One year follow-up of the cardio-metabolic profile evolution in renal transplant patients treated with alemtuzumab, cyclosporine, and steroids in a reference hospital in Colombia / John Fredy Nieto Ríos ; Catalina Ocampo Kohn ; Lina Maria Serna Higuita ; Arbey Aristizabal Álzate ; Harry Abadía Guzmán    

Público ISBD Título : One year follow-up of the cardio-metabolic profile evolution in renal transplant patients treated with alemtuzumab, cyclosporine, and steroids in a reference hospital in Colombia Otros títulos : Seguimiento por un año de la evolución del perfil cardiometabólico en pacientes trasplantados renales tratados con alemtuzumab, ciclosporina y esteroides en un hospital de referencia en Colombia Tipo de documento : documento electrónico Autores : John Fredy Nieto Ríos, ; Catalina Ocampo Kohn, ; Lina Maria Serna Higuita, ; Arbey Aristizabal Álzate, ; Harry Abadía Guzmán, Fecha de publicación : 2015 Títulos uniformes : Iatreia Idioma : Inglés (eng) Palabras clave : Cardiovascular disease  cardiovascular risk factors  Renal Transplantation Resumen : Introduction: Cardiovascular events occur 50 times more often in kidney transplant patients than in the general population and are the leading cause of death. The aim of the study was to evaluate the behavior of cardio-metabolic profile and determine the incidence of major cardiovascular events in the first year after transplantation. Methods: This prospective study evaluated the behavior of cardio-metabolic profile in adult patients that were transplanted during 2011. Results: The median age was 44.3 ± 12.05 years, 68.7 % were men and 95.5 %, hypertensive. Alemtuzumab-cyclosporine and steroids were used in 89.6 %, delaying the introduction of the antimetabolite. In the first year after transplantation there were three cases of diabetes mellitus, three major cardiovascular events, and 12 cases of acute rejection. Albumin, hemoglobin, weight, body mass index (BMI), calcium and HbA1C increased (p Mención de responsabilidad : John Fredy Nieto-Ríos, Narly Viviana Gómez-Rueda, Lina María Serna-Higuita, Catalina Ocampo-Kohn, Arbey Aristizábal-Alzate,Harry Abadía-Guzmán, Carlos Enrique Yepes-Delgado, Gustavo Zuluaga-Valencia Referencia : Iatreia. 2015;28(4):378-87. DOI (Digital Object Identifier) : 10.17533/udea.iatreia.v28n4a04 Derechos de uso : CC BY-NC-SA En línea : https://revistas.udea.edu.co/index.php/iatreia/article/view/19976 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3914 One year follow-up of the cardio-metabolic profile evolution in renal transplant patients treated with alemtuzumab, cyclosporine, and steroids in a reference hospital in Colombia = Seguimiento por un año de la evolución del perfil cardiometabólico en pacientes trasplantados renales tratados con alemtuzumab, ciclosporina y esteroides en un hospital de referencia en Colombia [documento electrónico] / John Fredy Nieto Ríos, ; Catalina Ocampo Kohn, ; Lina Maria Serna Higuita, ; Arbey Aristizabal Álzate, ; Harry Abadía Guzmán,  . - 2015. Obra : Iatreia Idioma : Inglés (eng) Palabras clave : Cardiovascular disease  cardiovascular risk factors  Renal Transplantation Resumen : Introduction: Cardiovascular events occur 50 times more often in kidney transplant patients than in the general population and are the leading cause of death. The aim of the study was to evaluate the behavior of cardio-metabolic profile and determine the incidence of major cardiovascular events in the first year after transplantation. Methods: This prospective study evaluated the behavior of cardio-metabolic profile in adult patients that were transplanted during 2011. Results: The median age was 44.3 ± 12.05 years, 68.7 % were men and 95.5 %, hypertensive. Alemtuzumab-cyclosporine and steroids were used in 89.6 %, delaying the introduction of the antimetabolite. In the first year after transplantation there were three cases of diabetes mellitus, three major cardiovascular events, and 12 cases of acute rejection. Albumin, hemoglobin, weight, body mass index (BMI), calcium and HbA1C increased (p Mención de responsabilidad : John Fredy Nieto-Ríos, Narly Viviana Gómez-Rueda, Lina María Serna-Higuita, Catalina Ocampo-Kohn, Arbey Aristizábal-Alzate,Harry Abadía-Guzmán, Carlos Enrique Yepes-Delgado, Gustavo Zuluaga-Valencia Referencia : Iatreia. 2015;28(4):378-87. DOI (Digital Object Identifier) : 10.17533/udea.iatreia.v28n4a04 Derechos de uso : CC BY-NC-SA En línea : https://revistas.udea.edu.co/index.php/iatreia/article/view/19976 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3914

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000495	AC-2015-048	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2015-048.pdf Adobe Acrobat PDF

Induction therapies in kidney transplantation: the experience of Hospital Pablo Tobon Uribe, Medellín, Colombia 2005-2010 / Catalina Ocampo Kohn ; Arbey Aristizabal Álzate ; John Fredy Nieto Ríos ; Harry Abadía Guzmán ; Walter Mario Ángel Jaramillo ; Carlos Ernesto Guzmán Luna ; Álvaro Mena Hurtado ; Juan José Vanegas Ruiz ; Catalina Vélez Echeverri ; Carlos Enrique Yepes Delgado ; Gustavo Adolfo Zuluaga Valencia  

Público ISBD Título : Induction therapies in kidney transplantation: the experience of Hospital Pablo Tobon Uribe, Medellín, Colombia 2005-2010 Tipo de documento : documento electrónico Autores : Catalina Ocampo Kohn, ; Arbey Aristizabal Álzate, ; John Fredy Nieto Ríos, ; Harry Abadía Guzmán, ; Walter Mario Ángel Jaramillo, ; Carlos Ernesto Guzmán Luna, ; Álvaro Mena Hurtado, ; Juan José Vanegas Ruiz, ; Catalina Vélez Echeverri, ; Carlos Enrique Yepes Delgado, ; Gustavo Adolfo Zuluaga Valencia, Fecha de publicación : 2011 Títulos uniformes : Transplantation Proceedings Idioma : Inglés (eng) Resumen : Background: Induction therapies in kidney transplantation have led to prescriptions of lower doses of maintenance immunosuppression and fewer acute rejection episodes. We sought to assess the use of an affordable monoclonal antibody in terms of the incidences of rejection episodes as well as graft and patient survivals and cytomegalovirus (CMV) and opportunistic infections among our kidney transplant recipients between August 2005 and December 2010. Data were obtained for patients who had more than 20 months’ follow-up. Materials and methods: We retrospectively analyzed data from kidney recipients between August 2005 and December 2010, using descriptive statistics and Kaplan-Meier survival analysis. We performed a multivariate analysis with logistic regression for the dependent variables of rejection episodes and death. Results: Among 425 transplant patients graft survival was 89.2% and patient survival was 94.1% after 76.2% of patients received alemtuzumab, 10.7% daclizumab, 3.6% basilix- imab, 2.4% thymoglobulin, and 7%, no induction therapy. Rejection incidence in general in the first year was 10.8% and CMV incidence 10%. There was an increased risk of rejection among subjects without any us with alemtuzumab induction therapy. Conclusion: Induction therapies show an important reduction in kidney transplant rejection incidence during the first year, allowing low doses of maintenance immunosuppressants, thereby diminishing long-term adverse effects. Alemtuzumab seemed to be a safe alternative with similar results to those obtained with standard immunosuppression. Mención de responsabilidad : C Ocampo, A Aristizabal, J Nieto, H Abadia, W Angel, C Guzman, A Mena, J Vanegas, C Velez, C Aguirre, C Yepes, G Zuluaga Referencia : Transplant Proc. 2011 Nov;43(9):3359-63. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2011.09.006 PMID : 22099796 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(11)01181-X Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3585 Induction therapies in kidney transplantation: the experience of Hospital Pablo Tobon Uribe, Medellín, Colombia 2005-2010 [documento electrónico] / Catalina Ocampo Kohn, ; Arbey Aristizabal Álzate, ; John Fredy Nieto Ríos, ; Harry Abadía Guzmán, ; Walter Mario Ángel Jaramillo, ; Carlos Ernesto Guzmán Luna, ; Álvaro Mena Hurtado, ; Juan José Vanegas Ruiz, ; Catalina Vélez Echeverri, ; Carlos Enrique Yepes Delgado, ; Gustavo Adolfo Zuluaga Valencia,  . - 2011. Obra : Transplantation Proceedings Idioma : Inglés (eng) Resumen : Background: Induction therapies in kidney transplantation have led to prescriptions of lower doses of maintenance immunosuppression and fewer acute rejection episodes. We sought to assess the use of an affordable monoclonal antibody in terms of the incidences of rejection episodes as well as graft and patient survivals and cytomegalovirus (CMV) and opportunistic infections among our kidney transplant recipients between August 2005 and December 2010. Data were obtained for patients who had more than 20 months’ follow-up. Materials and methods: We retrospectively analyzed data from kidney recipients between August 2005 and December 2010, using descriptive statistics and Kaplan-Meier survival analysis. We performed a multivariate analysis with logistic regression for the dependent variables of rejection episodes and death. Results: Among 425 transplant patients graft survival was 89.2% and patient survival was 94.1% after 76.2% of patients received alemtuzumab, 10.7% daclizumab, 3.6% basilix- imab, 2.4% thymoglobulin, and 7%, no induction therapy. Rejection incidence in general in the first year was 10.8% and CMV incidence 10%. There was an increased risk of rejection among subjects without any us with alemtuzumab induction therapy. Conclusion: Induction therapies show an important reduction in kidney transplant rejection incidence during the first year, allowing low doses of maintenance immunosuppressants, thereby diminishing long-term adverse effects. Alemtuzumab seemed to be a safe alternative with similar results to those obtained with standard immunosuppression. Mención de responsabilidad : C Ocampo, A Aristizabal, J Nieto, H Abadia, W Angel, C Guzman, A Mena, J Vanegas, C Velez, C Aguirre, C Yepes, G Zuluaga Referencia : Transplant Proc. 2011 Nov;43(9):3359-63. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2011.09.006 PMID : 22099796 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(11)01181-X Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3585

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000155	AC-2011-040	Archivo digital	Producción Científica	Artículos científicos	Disponible

---

1 (1 - 2 / 2) Por página: 25 50 100 200